Together, Takeda Pharmaceuticals and the Children’s National Hospital have created a program that aims to create and improve a standard of care for rare disease patients. As these patients often face major obstacles when it comes to diagnosis and receiving the best treatment, this program is extremely important.

About the Program

Titled the Rare Disease Clinical Activity Protocols (Rare-CAP) program, this program intends to remove the boundaries that stop patients, physicians, and other medical professionals from determining the proper diagnosis and care for rare diseases. It will implement a system to improve development, curation of protocols, and dissemination.

To make it the best that it can be, patient and caregiver input will be heavily taken into consideration. Additionally, the program will utilize a “wiki” format, through which medical professionals can input and view data, allowing for the sharing of ideas and further improvements.

The Rare Disease Institute of the Children’s National Research & Innovation Campus will lead this program, with Takeda supporting the launch and initial sustainability through a five-year commitment.

Find the source article here.